Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
January 28, 2020
Assignees:
Neurimmune Holding AG, University of Zurich
Inventors:
Jan Grimm, Fabrice Heitz, Fabian Wirth, Tobias Welt
Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
January 21, 2020
Assignees:
ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
Inventors:
Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
Abstract: The first embodiment of the present invention is a method for purifying an antibody or a substance derive from an antibody, wherein a carrier 1 having an affinity ligand with affinity for the antibody or the substance derived from the antibody and a carrier 2 having a cation exchange group are used to prepare an integrated column 1 connecting a column containing the carrier 1 and a column containing the carrier 2 or a column 2 having the mixture of the carrier 1 and carrier 2, the antibody or the substance derived from the antibody is applied to the column 1 or the column 2, and then the adsorbed antibody or substance derived from the antibody is eluted from the column 1 or the column 2. The second embodiment of the present invention is a method for using a carrier having a cation exchange group, wherein a solution containing an antibody or a substance derived from an antibody is applied to a carrier having a cation exchange group having a carboxyl group-containing ligand and pKa of 4.
Abstract: The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal, of protein, fragments without adversely affecting the yield of the desired protein product.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
December 31, 2019
Assignee:
Merck Patent GmbH
Inventors:
Mikhail Kozlov, Matthew T. Stone, Romas Skudas, Kevin Galipeau
Abstract: This application relates to methods for purification of proteins such as antibodies using a hydrophilic polymer (e.g., PEG), a fatty acid (e.g., caprylic acid), and/or another agent (e.g., calcium chloride).
Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
December 10, 2019
Assignees:
University of Cincinnati, E. R. Squibb & Sons, L.L.C.
Inventors:
Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.
Abstract: The present invention relates to the purification of immunoglobulins and the problem of providing a method for purifying an immunoglobulin in an efficient and cost-effective manner and with satisfactory purity and yield. In particular, the present invention addresses the aspect of the re-use of the rather cost-intensive chromatography materials, in particular the lifetime of the chromatography materials used in the capture step of the downstream process, and how this can be increased while reducing the technical complexity of the purification process.
Type:
Grant
Filed:
March 9, 2015
Date of Patent:
November 26, 2019
Assignee:
RICHTER GEDEON NYRT.
Inventors:
Ferenc Felföldi, Zsuzsa Benkö, Melinda Gáspár
Abstract: The present invention provides methods for increasing purity of an Fc-containing protein by removing protein aggregates during the Protein A chromatography step used during the purification of the Fc-containing protein.
Abstract: A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
Type:
Grant
Filed:
March 3, 2016
Date of Patent:
November 12, 2019
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
Abstract: This disclosure relates to recombinant proteins comprising a GM-CSF sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises N-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer.
Type:
Grant
Filed:
April 13, 2015
Date of Patent:
November 5, 2019
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.
Type:
Grant
Filed:
March 14, 2016
Date of Patent:
October 29, 2019
Assignee:
NovImmune SA
Inventors:
Nicolas Fouque, Jean François Depoisier, Keith Wilson, Judith Vajda, Egbert Müller, Romain Dabre
Abstract: The present invention refers to a method for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies.
Type:
Grant
Filed:
February 18, 2015
Date of Patent:
October 29, 2019
Assignee:
Merck Patent GmbH
Inventors:
Romas Skudas, Matthias Joehnck, Bianca Edelmann, Simon Braun, Mikhail Kozlov, Matthew T. Stone, Kevin Galipeau
Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
October 15, 2019
Assignee:
BiOrion Technologies B.V.
Inventors:
Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
Abstract: The present invention relates generally to a method of diagnosing, prognosing or monitoring the development or progress of metastatic cancer, more particularly bone metastatic cancer. The method of the present invention more particularly provides a method for detecting metastatic cancer, or a predisposition thereto, by screening for the differential expression of a panel of genes which comprise an IRF7 binding site. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating metastatic cancer, in particular bone metastatic cancer. More particularly, the present invention provides a means of therapeutically or prophylactically treating metastatic cancer by upregulating type I IFN levels.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
October 15, 2019
Assignee:
LA TROBE UNIVERSITY
Inventors:
Belinda Sheree Parker, Paul John Hertzog
Abstract: Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
October 15, 2019
Assignee:
Biomet Biologics, LLC
Inventors:
Matthew D. Landrigan, Krista Toler, Jennifer E. Woodell-May, David L. Suter
Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
October 1, 2019
Assignee:
JANSSEN PHARMACEUTICA NV
Inventors:
Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
September 24, 2019
Assignee:
PRECISION IBD, INC.
Inventors:
Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh